For medical devices the authorisation to sell is granted to the firm you appoint, and ending that appointment is a statutory ground for revoking it rather than a way of moving it to somebody else. The registration stays where it was granted, or it goes. Choosing a partner here is choosing who holds your access. We find the candidates and establish what each of them can actually carry.
Around seventy per cent of medical device supply here is still imported, on the health ministry’s own account, with the domestic industry holding roughly a tenth of its own market — though the number of registered device companies rose from a hundred and twenty-three in 2015 to eight hundred and ninety-one by 2021. The direction of travel is explicit government policy rather than market drift, and it is working: the imported share of public catalogue purchasing fell from about eighty-eight per cent in 2019 and 2020 to around seventy in 2021 and 2022.
For medicines the policy is sharper still. An imported drug must be produced domestically within five years, or follow a technology-transfer roadmap, and international non-proprietary name generics circulating here may only be made by domestic pharmaceutical industry. So a medicines strategy built on indefinite import is a strategy with a stated expiry date on it.
The public buyer matters more than in most markets, and it buys through a sectoral electronic catalogue. Hospitals are paid per case under the national case-mix system, with devices bundled into the case payment rather than reimbursed separately — which means a premium device competes inside a fixed tariff rather than on its merits. The national formulary and device compendium decide what can be used inside the insurance scheme at all.
And the rules themselves have just moved. In May 2026 a single instrument repealed forty health ministry regulations at once, including the one that had governed device registration and distributor appointment since 2017, with a one-year transition running to May 2027. Anything written about this market before that date needs re-reading, and we have been careful on this page to say which rules are current and which describe the design that was just replaced.
The mechanics are worth reading closely, and they moved in May 2026, when a single instrument repealed forty health ministry regulations at once with a transition running to May 2027. What survives is the shape. Only one appointed licence holder may act for an imported brand from a given manufacturer, so this is a single-partner market rather than a multi-agent one, and termination of that appointment by the manufacturer is expressly a ground for revoking the product’s registration. Under the regime just replaced, the authorisation also ran no longer than the appointment behind it, a mid-term handover needed the outgoing party to agree, and a dispute that dragged on ended in revocation with nobody able to sell. Read that as the design intent, and check the current standard for your own product class before anyone signs.
Two more things shape the shortlist. Medicines work differently from devices — the registrant has to be a licensed Indonesian pharmaceutical manufacturer, not a wholesaler, so a wholesaler offering to hold your registration is telling you something about itself. And coverage is countable rather than assertable: a wholesale branch is recognised province by province and may only distribute in the province that recognised it. The market is also genuinely fragmented, with thousands of registrants and no firm holding more than a sliver of the register, so you are doing the choosing.
The channel sorts into five types: distribution arms captive to the big Indonesian pharmaceutical groups; the Indonesian operation of a global distribution multinational; specialist device and capital-equipment houses; state-owned distributors; and regional sub-distributors covering one or two provinces. The largest listed distribution arm describes something in the order of seventy branches across its group with three distribution centres and a warehouse at every branch — though a third-party database gives a materially lower branch count, so treat the figure as contested.
What makes coverage checkable here rather than rhetorical is a licensing fact: each warehouse location needs its own distribution licence. In a country of seventeen thousand islands, “national coverage” is therefore a count of licensed branches, not a claim on a map. Ask for the licence schedule by location and compare it with the sales territory they describe. The gap is the real footprint.
A second fact makes it harder still to fake. Premises must be owned or leased for a minimum term, and a virtual office does not qualify. So “we have a branch in Makassar” is answerable with a lease. Add the cold-chain requirements for temperature-sensitive lines, and the workshop and qualified-technician requirements for electromedical and radiation devices, and the number of genuinely national device distributors is small.
For medicines the structure is different in kind. The registrant must be a licensed Indonesian pharmaceutical manufacturer, not a wholesaler — so a wholesaler offering to hold your medicine registration is telling you something about itself. Appointing a distributor does not get you a registration at all. That is the cleanest line between the two halves of this market and it is worth establishing before any commercial conversation.
For devices the list is long and checkable. For medicines the first question is whether your counterparty can lawfully hold anything at all.
This market rewards asking for registers and leases rather than for references. Almost everything that matters is a document with a location on it.
Then ask for the licence covering every warehouse they claim. A sales map showing more cities than licensed warehouses is your answer about coverage, and it takes one email to obtain.
Plus the date of their last internal audit. It has been required for electronic catalogue display since the beginning of 2025, so a candidate without one cannot sell to the public sector however good its hospital relationships are.
With the qualification and the appointment letter. For electromedical lines ask additionally for the workshop address and the technician’s certificate, and for radiation devices the radiology technician. These are people, and people leave.
Showing a term that meets the minimum and a physical address. The rule excluding virtual offices exists because the practice existed, so this is a real check rather than a formality.
It shows you the holder’s name, the expiry date and exactly what your own certificate will look like — including whose name will be on it. That single document makes the structural issue concrete in a way no explanation does.
With its legalisation requirement and its stated term. Then ask them, directly, what happens to the registration if the appointment ends. The answer tells you whether they understand their own leverage, and whether they will say so.
Under the regime just replaced, a registration showing no distribution activity over a two-year period could not be renewed. A distributor who warehouses your brand without selling it is a risk to the registration itself, not merely to your forecast.
A newly listed imported device goes into a frozen state in the public catalogue and is hidden pending review of domestic capacity. A distributor who has run that argument has the production-adequacy documentation and knows the process. One who has never run it has never sold to the public sector.
It is held by one entity per product, and termination of the appointment by the manufacturer is a statutory ground for revoking it. A switch therefore means re-registration under the new entity rather than a transfer, with the cost and the delay that implies, and the outgoing party has every reason to be unhurried.
A newly listed imported device is placed in a frozen state and hidden, under a ministerial decision in force since July 2022, pending a review of whether domestic capacity can meet national need or whether the specification can be made locally. Nothing has gone wrong when this happens. It is the design.
Filed after expiry, a renewal is treated as a fresh application, and an expired product may not be distributed in the meantime. The window opens months before expiry. This is a diary problem that becomes a supply problem.
Under the replaced regime, nil reported activity over two years blocked renewal outright. Whatever the current standard says, the structural lesson holds: a distributor that holds your registration and does not trade it is a liability of a particular and under-appreciated kind.
Imported drugs must be produced domestically within five years or follow a technology-transfer roadmap, and generics under international non-proprietary names may only be made by domestic industry. An import model here has a stated shelf life.
Forty health ministry regulations were repealed by one instrument in May 2026, with a one-year transition and a shorter window for certain pharmaceutical import approvals. Sanctions run from written warning through fines, suspension, recall and destruction, system blocking and blacklisting, to licence revocation. Build the regulatory review into the agreement.
Not as a foreign entity. The marketing authorisation is applied for by a licensed Indonesian distributor holding a distribution licence and a good distribution practice certificate, appointed by the manufacturer through a legalised agency letter. Your realistic options are to appoint a distributor, to establish and licence your own Indonesian entity, or to use a neutral licence-holder arrangement.
No. It is held by one entity per product at a time and is not transferable, and termination of the appointment by the manufacturer is expressly a ground for revoking it under the regulation that took effect in May 2026. Plan for re-registration under the incoming partner, and plan the timing before you serve notice rather than after.
Be careful with anything you read on this, including older guidance. Under the regulation repealed on 4 May 2026 it ran for up to five years and followed the term of the appointment letter, which itself had to be between two and five years. The replacement sets no validity period in the text we could read and defers to other legislation, so each licence records its own expiry. Check the current standard for your product class rather than relying on the old rule.
No, and this is the sharpest difference between the two halves of this market. A medicine may only be registered by an Indonesian pharmaceutical manufacturer, with written approval from the foreign manufacturer. Appointing a wholesaler does not produce a registration. On top of that, an imported drug must be produced domestically within five years or follow a technology-transfer roadmap.
Because it is probably frozen, by design. Newly listed imported devices are placed in a frozen state and hidden from the sectoral electronic catalogue under a ministerial decision effective July 2022, until it is shown that domestic capacity cannot meet national need or that the specification cannot be produced locally. Your distributor needs the production-adequacy documentation to make that argument.
A count of licences and leases. Each warehouse location requires its own distribution licence, and premises must be owned or leased on a minimum term with virtual offices excluded. So ask for the licence schedule by location and the lease for each, and compare it with the territory they describe. In an archipelago, that gap is the single most useful thing you can learn about a candidate.
Appointing a distributor here is appointing the holder of your market access, for exactly as long as the agreement runs. That is worth getting right first time. Tell us what you are placing and we will come back with the structure and the shortlist together.
How we verify How a distributor search runs